Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
591.85
-11.41 (-1.89%)
At close: May 28, 2025, 4:00 PM
590.50
-1.35 (-0.23%)
After-hours: May 28, 2025, 5:27 PM EDT
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $3.03B in the quarter ending March 31, 2025, a decrease of -3.70%. This brings the company's revenue in the last twelve months to $14.09B, up 7.52% year-over-year. In the year 2024, Regeneron Pharmaceuticals had annual revenue of $14.20B with 8.27% growth.
Revenue (ttm)
$14.09B
Revenue Growth
+7.52%
P/S Ratio
4.52
Revenue / Employee
$932,457
Employees
15,106
Market Cap
62.54B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
REGN News
- 1 hour ago - Mary Kay Inc. Awards 10 Grants to Young Innovators at 2025 Regeneron International Science and Engineering Fair - Business Wire
- 9 hours ago - Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis - Business Wire
- 6 days ago - Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma - GlobeNewsWire
- 7 days ago - What Regeneron's Purchase Of 23andMe Means For Your Genetic Privacy - Forbes
- 7 days ago - Regeneron's 23andMe Steal: Smart Genetics Play That Won't Cure Near-Term Growth Pains - Seeking Alpha
- 8 days ago - Regeneron Pharmaceuticals, Inc. (REGN) RBC Capital Markets Global Healthcare Conference (Transcript) - Seeking Alpha
- 8 days ago - Viz.ai Announces Collaboration With Sanofi and Regeneron to Improve Management and Care of Chronic Obstructive Pulmonary Disease (COPD) - Business Wire
- 9 days ago - Regeneron acquires bankrupt 23andMe, pledges ethical use of genetic data - Invezz